September 2013, Vol 2, No 6
Illustrating the New Era of Personalized MedicineLetter to Our Readers
It gives us great pleasure to present this issue of Personalized Medicine in Oncology (PMO). Over the past several months, we have thoroughly examined every aspect of the journal – appearance, readability, and most importantly, editorial content.
You will see the result of our efforts in the following ways:
The immune system is back in the discussion of how to fight cancer. Many exciting new agents are being studied in clinical trials in diseases such as non–small cell lung cancer, melanoma, and kidney cancer, to name just a few. PMO will keep readers up to date on advances in this area and discuss what it means for patients.
• Interview With the Innovators
The world of personalized medicine is a rapidly changing, ever-evolving state involving many stakeholders on the front lines of its creation: physicians, industry, researchers, patient advocates, and payers. PMO seeks out the leaders in these sectors and brings you their game-changing strategies, missions, and impact on personalized oncology care.
• The Last Word
In this department, our Strategic Editor and Editor in Chief sum up thoughts on various overriding themes in the world of personalized medicine.
• Journal Design
You will notice a redesign in the look of the entire journal. This new, streamlined design is intended to make the journal easier to read and navigate.
We believe these will greatly enhance your reading experience. Please let us know what you think! E-mail our Editorial Director, Kristin Siyahian at firstname.lastname@example.org. We look forward to and welcome your feedback.
Al Benson, MD
Editor in Chief
Personalized Medicine in Oncology
Hollywood, FL – Genomic profiling of individual tumors represents a paradigm shift in oncology and holds great promise for patients, according to Gary Palmer, MD, JD, MBA, MPH, Senior Vice President, Medical Affairs and Commercial Development, Foundation Medicine, who described this new genomic assay at the Third Annual Conference of [ Read More ]
Bevacizumab maintenance therapy following induction with bevacizumab-based chemotherapy significantly increases progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC). However, the addition of erlotinib in the maintenance phase does not increase overall survival (OS) compared with bevacizumab alone. KRAS status was not a predictor of benefit from erlotinib in [ Read More ]